Thomas Gajewski to Sulfonamides
This is a "connection" page, showing publications Thomas Gajewski has written about Sulfonamides.
Connection Strength
0.777
-
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res. 2017 07 01; 23(13):3269-3276.
Score: 0.432
-
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019 08; 20(8):1083-1097.
Score: 0.128
-
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer. 2019 03 20; 7(1):80.
Score: 0.126
-
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65.
Score: 0.091